Cervical Cancer – Epidemiology – Epidemiology Dashboard
DRG Epidemiology’s coverage of cervical cancer comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of renal cell carcinoma for each country, as well as annualized case counts projected to the national population.
In addition to forecasting cervical cancer incident and prevalent patient populations, we estimate the number of drug-treatment opportunities in specific lines of therapy.
DRG Epidemiology’s forecast will answer the following questions:
In developing countries, what impact will economic growth and development have on the number of people diagnosed with ovarian cancer each year?
Of all people diagnosed with cervical cancer, how many in each of the major mature pharmaceutical markets are drug-treated?
How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of cervical cancer over the forecast period?
All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is provided for full transparency into research and methods. In addition, we provide a graph depicting the patient flow between or within different disease states for the major mature pharmaceutical markets. These patient-flow diagrams are provided at the regional level but may be requested for any specific country or forecast year.
Cervical Cancer - Epidemiology - Epidemiology Dashboard
Introduction
Cervical Cancer Epidemiology Dashboard
Jai Oberoi
Jai Oberoi, M.P.H., isan associate epidemiologist at Clarivate. His areas of interest are oncology and real-world data analysis. Previously, he was a research specialist at Emory University, where he analyzed whole genome/exome data. He obtained his M.P.H. in epidemiology and applied biostatistics from Columbia University, where he conducted research on the phenotypic and genotypic markers of aging.
Oliver Blandy, M.Sc.
Oliver Blandy, M.Sc., is a senior epidemiologist at Clarivate. Previously, Oliver worked as a research assistant for Imperial College London, where he was the lead for several studies within an NIRH-funded research group investigating healthcare-associated infections and antimicrobial resistance. He holds an M.Sc. from the University of Bristol, where he specialized in nutrition, physical activity, and public health. He also holds a B.Sc. in chemistry and a postgraduate certificate in education, both from the University of Bristol.
